Table 1.
Summary of patient’s characteristics and dosimetry measurements
| Total (n = 90) | |
|---|---|
| Gender, n (%) | |
| Female | 47 (52%) |
| Male | 43 (48%) |
| Age, years | |
| Mean (SD) | 64 (13) |
| Median [range] | 66 [16–87] |
| IQR | 56–71 |
| Primary site, n (%) | |
| Appendix | 1 (1%) |
| Caecum | 2 (2%) |
| Gastric | 1 (1%) |
| Pancreas | 35 (40%) |
| Pancreas and Gastric | 1 (1%) |
| Rectum | 4 (5%) |
| Retroperitoneum | 1 (1%) |
| Sacral or presacral | 3 (3%) |
| Sigmoid | 1 (1%) |
| Small bowel | 39 (44%) |
| Unknown | 2 |
| Tumour grading, n (%) | |
| G1 | 15 (19%) |
| G2 | 50 (61%) |
| G3 | 16 (20%) |
| Unknown | 9 |
| Number of Lu-177 cycles, n (%) | |
| 2 | 12 (13%) |
| 3 | 17 (19%) |
| 4 | 57 (63%) |
| 5 | 4 (4%) |
| Cumulative Lu-177 activity, GBq | |
| Mean (SD) | 27.4 (7.8) |
| Median [range] | 28.4 [11.8–52.5] |
| IQR | 22.4–32.2 |
| Radiosensitising chemotherapy (RSC), n (%) | |
| No | 29 (32%) |
| Yes | 61 (68%) |
| Number of cycles with RSC, n (%) | |
| 1 | 11 (18%) |
| 2 | 11 (18%) |
| 3 | 31 (51%) |
| 4 | 8 (13%) |
| Baseline phenotype, n (%) | |
| GaTate vol greater than FDG | 31 (36%) |
| GaTate vol same as FDG | 6 (7%) |
| GaTate + and FDG- | 20 (23%) |
| No FDG | 33 (34%) |
| Index lesion cycle 1 radiation dose, Gy | |
| Mean (SD) | 46 (41) |
| Median [range] | 35 [8–217] |
| IQR | 23–57 |
| Index lesion cumulative radiation dose, Gy | |
| Mean (SD) | 110 (78) |
| Median [range] | 88 [11–380] |
| IQR | 56–152 |
| Measurable lesion cycle 1 Radiation Dose, Gy | |
| Mean (SD) | 34 (24) |
| Median [range] | 29 [5–135] |
| IQR | 18–47 |
| Measurable lesion cumulative Radiation Dose, Gy | |
| Mean (SD) | 88 (56) |
| Median [range] | 77 [8–244] |
| IQR | 47–116 |
| Combined lesions cycle 1 Radiation Dose, Gy | |
| Mean (SD) | 33 (24) |
| Median [range] | 27 [5–135] |
| IQR | 17–45 |
| Combined lesions cumulative radiation dose, Gy | |
| Mean (SD) | 87 (57) |
| Median [range] | 74 [8–238] |
| IQR | 45–117 |